Adverum Biotechnologies Long Term Debt

Adverum Biotechnologies (ADVM) currently reports a long-term debt of $83M as of September 2025. That compares with $63M in the prior-year period — up 32.8% year over year. Use the charts on this page to explore Adverum Biotechnologies's long-term debt history and peer comparisons.

Adverum Biotechnologies's long-term debt increased from $63M to $83M — a 32.8% year-over-year increase (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adverum Biotechnologies reported $83M in long-term debt as of September 2025. That compares with $63M in the prior-year period — up 32.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $83M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adverum Biotechnologies, and consider following ADVM for alerts when major investors trade the stock.

Adverum Biotechnologies is classified in the Healthcare sector. On long-term debt, it currently shows $83M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADVM with unrelated industries.